Patients With Suspected or Diagnosed Central Nervous System Lymphoma
Conditions
Brief summary
The overall goal of this imaging trial is to prospectively compare the usefulness of 18F-FDG PET and 18F-FET PET in evaluating treatment response and predicting prognosis in patients with central nervous system lymphoma.
Interventions
DRUG[18F]FET
Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor
Sponsors
Asan Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
In order to be eligible for participation in this trial, the subject must: * Be ≥ 19 years of age. * Patients diagnosed with central nervous system lymphoma by surgery/biopsy or suspected of central nervous system lymphoma by anatomical imaging examination such as MRI. * Patients who have results or are planning to examine 18F-FDG PET in the above patients.
Exclusion criteria
The subject must be excluded from participating in the trial if the subject fulfil any single criteria described below: * Pediatric and adolescent patients under 19 years of age. * The patient is pregnant, is attempting to become pregnant, or is nursing (breast-feeding) to children. * Patients with diagnosed or suspected lymphoma lesions in organs other than the cetral nervous system. * Based on the investigator's judgement, if the patient makes it impossible to collect complete data for a clinical trial due to personal or other reasons. * Patients who cannot stably have PET/CT due to claustrophobia, dyskinesia, anxiety disorder, seizure, etc. * Based on the investigator's judgement, if the patient has a serious and/or uncontrolled and/or unstable medical disease (e.g., congestive heart failure, acute myocardial infarction, severe lung disease, chronic renal disease or chronic liver disease, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of target to background ratio between baseline, mid-therapy and end-of treatment PET in patients with primary central nervous system lymphoma | 20-40 minutes post injection |
Secondary
| Measure | Time frame |
|---|---|
| 1.5 year progression free survival | 18months |
Countries
South Korea
Contacts
Primary ContactMinyoung Oh, M.D.,Ph.D.
Outcome results
None listed